Tech Company Financing Transactions
Thetis Pharmaceuticals Funding Round
Connecticut Innovations, Stonehenge Capital and private investors joined a $1.5 million venture round for Thetis Pharmaceuticals. The financing round closed on 8/22/2011.
Transaction Overview
Company Name
Announced On
8/22/2011
Transaction Type
Venture Equity
Amount
$1,500,000
Round
Undisclosed
Investors
Connecticut Innovations (David Wurzer)
Proceeds Purpose
The company expects to begin clinical studies with TP101 in 2012, an exceptionally rapid timeline made possible by certain regulatory efficiencies associated with the metformin / omega-3 chemical composition of the drug candidate.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
23 Business Park Dr.
Branford, CT 06405
USA
Branford, CT 06405
USA
Phone
Website
Email Address
Overview
Thetis Pharmaceuticals is a privately held biopharmaceutical company applying its HEALER technology to discover and develop innovative drugs for the treatment of gastrointestinal and cardiometabolic diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Gary Mathias
Chief Medical Officer
Brian Harvey
President
Frank Sciavolino
VP - Bus. Development
Aaron Mathias
VP - R & D
Matthew Hanley
Browse more venture capital transactions:
Prev: 8/22/2011: Sentilla venture capital transaction
Next: 8/22/2011: 6fusion venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs